To construct a signature to predict the prognosis and the effect of immunotherapy in patients with CM, we constructed an ICPBS based on seven ICPs (CD40, CD80, CD86, ICOSLG, KIR3DL1, LAG3, and TNFSF4), which could independently predict the prognosis of CM. This evidence concerns the gene TNFSF4 and cutaneous mastocytosis.